Sign in
CompletedPhase 4

Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea

Key facts

Who runs it
China Medical University Hospital
Where
Taiwan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
45 people enrolled
Started
5 Nov 2024
Ended
22 Oct 2025
Type of study
Interventional, 3 groups
Treatments tested
  • Atomoxetine 80mg combined with oxybutynin 5mg
  • Venlafaxine 37.5mg
  • oxybutynin 5mg combined with trazodone 100mg
  • Placebo
Record updated
23 April 2026

Who can take part

Age
20 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • apnea-hypopnea index ≥ 15 hr-¹

Who cannot take part

  • current use of continuous positive airway pressure therapy
  • use of drugs that might interact with the investigational medication or known to affect sleep during the trial or 1 month before the study
  • the presence of pulmonary, cardiac, neurologic, or other active severe medical or psychiatric diseases
  • known allergy to the investigational medication
  • current smoking
  • heavy alcohol drinking (male > 14 drinks and women >7 drinks per week)
  • pregnant or lactating
  • periodic limb movement index > 15hr-1
  • the presence of sleep-related hypoventilation

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study will conduct 3 intervention trials with 44 different participants in each trial, with 22 participants will undergo in-laboratory overnight polysomnograms (PSGs) at one night of medication intervention, and the other 22 at taking placebo (contained starch) 1 h before sleep. Three medication regimens will be tested: (1) atomoxetine 80mg combined with oxybutynin 5mg; (2) venlafaxine 37.5mg; and (3) oxybutynin 5mg combined with trazodone 100mg. Endotypic traits will be estimated using the Phenotyping Using Polysomnography method. The primary outcome is the change in apnea-hypopnea index, and secondary outcomes include endotypic traits and sleep parameters.

The 3 groups in the trial

  • atomoxetine 80mg combined with oxybutynin 5mgTreatment being tested

    Participants will receive atomoxetine 80mg combined with oxybutynin 5mg once (1 h before polysomnographic study).

    Treatment: Atomoxetine 80mg combined with oxybutynin 5mg and Placebo

  • venlafaxine 37.5mgTreatment being tested

    Participants will receive venlafaxine 37.5mg once (1 h before polysomnographic study).

    Treatment: Venlafaxine 37.5mg and Placebo

  • oxybutynin 5mg combined with trazodone 100mgTreatment being tested

    Participants will receive oxybutynin 5mg combined with trazodone 100mg once (1 h before polysomnographic study).

    Treatment: oxybutynin 5mg combined with trazodone 100mg and Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
23 April 2026